JAK Inhibitors Boost Immunotherapy Response Rates in Lung Cancer and Lymphoma Trials
核心洞察
Two clinical trials demonstrated that combining JAK inhibitors with immune checkpoint inhibitors significantly improved tumor response rates compared to checkpoint inhibitors alone in lung cancer and lymphoma patients.
In the lung cancer trial, 67% of patients experienced tumor shrinkage with the combination therapy, substantially higher than typical response rates of less than 50% with pembrolizumab monotherapy.
The lymphoma study showed 53% response rates in patients whose tumors had previously stopped responding to checkpoint inhibitors, with 46% remaining progression-free at two years.
Two separate clinical trials have demonstrated that combining JAK inhibitors with immune checkpoint inhibitors can dramatically improve cancer treatment outcomes, offering new hope for patients with lung cancer and lymphoma whose tumors typically resist standard immunotherapy approaches.
The breakthrough findings, published in Science, show that this combination strategy addresses a fundamental limitation of checkpoint inhibitors, which typically work for only 15% to 60% of cancer patients despite their potential for remarkable long-term responses.
Lung Cancer Trial Shows Substantial Improvement
In a phase 2 clinical trial led by Andy Minn, M.D., Ph.D., of the University of Pennsylvania Perelman School of Medicine, 21 patients with metastatic non-small cell lung cancer received pembrolizumab (Keytruda) combined with the JAK inhibitor itacitinib. The results were striking: tumors partially or completely shrank in 14 of the 21 participants (67%), and the treatment kept tumors at bay for a median of more than 2 years.
These outcomes represent a significant improvement over historical data. In other clinical trials, pembrolizumab as an initial treatment for metastatic non-small cell lung cancer typically shrinks tumors in less than half of patients, and among those who do respond, the treatment usually stops tumor growth for only a few months.
"The two trials involved people with different types of cancer, treated with different JAK inhibitors and immune checkpoint inhibitors, and with different timing of each drug's administration," Dr. Minn noted. "And yet we both reached the same conclusion, which to me is just really remarkable and provides a lot of motivation and hope that we're on to something."
Lymphoma Patients See Renewed Response
The second trial, led by John Teijaro, Ph.D., of Scripps Research Institute, focused on an even more challenging patient population: 19 people with Hodgkin lymphoma who had previously received checkpoint inhibitors that either hadn't worked or had worked only marginally.
When immune checkpoint inhibitors fail for people with Hodgkin lymphoma, few treatment options remain. "Their [cancer is] resistant to most [drugs] by that time. This is a really tough patient population to treat," Dr. Teijaro explained.
However, when nivolumab (Opdivo) was reintroduced with the JAK inhibitor ruxolitinib (Jakafi), tumors shrank in 10 people (53%), including six patients whose tumors disappeared completely. Two years after the start of the trial, 46% of participants had no sign of their cancer growing back, compared to just 23% in a small clinical trial of people with lymphoma who received nivolumab and another drug after nivolumab alone stopped working.
Resolving the Timing Paradox
The success of this combination initially seemed counterintuitive, as JAK proteins are critical for checkpoint inhibitors to work, suggesting that blocking them would reduce effectiveness. However, the research teams discovered that timing is crucial.
The researchers suspect that an initial, short burst of JAK-led inflammation activates T cells, setting the stage for immune checkpoint inhibitors to unleash the T cells against tumors. But if JAK proteins keep signaling continuously, chronic inflammation develops and cancer-killing T cells become exhausted.
"We had a lot of data that was pointing in this paradoxical direction," Dr. Minn said. The solution was to use JAK inhibitors to cool chronic inflammation while preserving the initial spark needed for checkpoint inhibitors to work effectively.
Mechanisms of Enhanced Immune Response
When researchers analyzed immune cell populations in both patients and mice, they found that the combination treatment substantially altered the numbers and activities of various immune cells. As hoped, they observed increased numbers of reinvigorated T cells in many patients.
However, JAK inhibitors appear to do more than help exhausted T cells. In the lymphoma trial, the treatment produced "an even more dramatic change in myeloid cells," especially in people whose tumors completely disappeared, according to Jaroslav Zak, Ph.D., another member of the Scripps team.
Myeloid cells are immune cells that can either restrain T cells or help them grow. The JAK inhibitor tipped the scales, pushing myeloid cells to be more helpful than harmful. These findings raise "hopes for myeloid [cell] modulation in the context of cancer therapy," Dr. Zak said.
Safety Profile and Future Directions
Side effects were infrequent in both trials, and none of the patients in the lymphoma trial had to stop treatment due to adverse effects. Even anemia, which is quite common with ruxolitinib, was not severe enough to require treatment discontinuation in most patients.
Despite these promising results, significant questions remain. "There's still a long way to go in understanding how this works, what the best course is for patients, what the best JAK inhibitor is, when you should give it, and what dose you should give. They're all open questions that need to be investigated," Dr. Teijaro noted.
The research represents an important trend in cancer immunotherapy sophistication. "We are becoming more sophisticated in the ways we manipulate the immune response [to cancer]," said Grégoire Altan-Bonnet, Ph.D., of NCI's Laboratory of Integrative Cancer Immunology, who wasn't involved in either study.
However, additional data suggested that there's a limit to what JAK inhibitors can do if a patient's T cells are completely exhausted, which may explain why the combination didn't work for everyone. Future research will need to identify biomarkers that can predict which patients are most likely to benefit from this combination approach.